Vanguard Global Infrastructure ETF (VBLD) Stock Price, News, Quotes-Moomoo

AU ETFDetailed Quotes

VBLD Vanguard Global Infrastructure ETF

Watchlist

69.280
-0.580-0.83%

20min DelayMarket Closed Nov 8 16:00 AET

69.700High68.950Low

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Investors Elect to Accelerate Market on Election Week | Weekly Buzz
Kevin Travers16:26 ET
Friday Market Finished with Records | Wall Street Today
Kevin Travers16:15 ET
TSLA Up, China Down, Friday Market Quiet After Loud, Decisive Week | Live Stock
Kevin Travers11:05 ET
FOMC Cut Sends Prices Up, Election Blitz Strong | Wall Street Today
Kevin TraversNov 7 16:26 ET
Duke Energy Corporation (DUK) Q3 2024 Earnings Call Transcript Summary
moomoo AINov 7 13:48 ET · Conference Call
Nasdaq 100 Extends Record Levels Ahead Of Fed Meeting, Tesla Hits 26-Month Highs, Small Caps Stall: What's Driving Markets Thursday?
BenzingaNov 7 13:37 ET

Comments

Moomoo AI

Oct 17, 2023 02:08

The trial of VB-601 may add value but hiring an advisor for strategic options and reporting losses indicate resource pressure and strategy shift, thus casting doubt on future performance.

Press Release: VBL Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Moomoo AI

Oct 17, 2023 02:04

Matthew Trudeau's appointment as CCO massively benefits VBL, given his extensive experience in leading commercial practices at different biotech firms. His expertise is expected to be crucial in preparing for the anticipated OVAL Phase 3 trial readout in the second half of 2022.

Press Release: VBL Therapeutics Announces Appointment of Matthew Trudeau as Chief Commercial Officer

Moomoo AI

Oct 17, 2023 02:04

EIC Accelerator funds VBL as it approaches the final enrollment phase of its key product candidate, ofra-vec (VB-111), for ovarian cancer. The CEO perceives this investment as acknowledgment of the potential ofra-vec offers to patients and the current critical need in ovarian cancer therapies.

Press Release: VBL Therapeutics Selected for EUR17.5 Million of Funding from Horizon Europe EIC Accelerator Program